A B S T R A C T As demonstrated by others, fibrinolytic activity was generated in diluted, acidified normal plasma exposed to kaolin, a process requiring Hageman factor (Factor XII). Generation was impaired by adsorbing plasma with glass or similar agents under conditions which did not deplete its content of Hageman factor or plasminogen. The defect could be repaired by addition of a noneuglobulin fraction of plasma or an agent or agents eluted from diatomaceous earth which had been exposed to normal plasma. The restorative agent, tentatively called Hageman factor-cofactor, was partially purified by chromatography and had an apparent molecular weight of approximately 165,000. It could be distinguished from plasma thromboplastin antecedent (Factor XI) and plasma kallikrein, other substrates of Hageman factor, and from the streptokinase-activated pro-activator of plasminogen. Evidence is presented that an additional component may be needed for the generation of fibrinolytic activity in mixtures containing Hageman factor, HF-cofactor, and plasminogen.
INTRODUCTION
Plasminogen, a normal constituent of human plasma, is the precursor of plasmin, a protease of broad specificity. The conditions which lead to its activation are still uncertain. Hypotheses suggesting the existence of a physiologic blood activator of plasminogen (1, 2) , whose level is enhanced by various stresses (3) (4) (5) (6) (7) (8) (9) , are supported by a considerable volume of experimental evidence (10) (11) (12) . The origin of this plasminogen activator is uncertain, although vascular endothelial cells have been implicated (13) ..
The fibrinolytic properties of normal human plasma, presumably due to the generation of plasmin, are greatly enhanced by incubation with kaolin after acidification and lowering of the ionic strength (14, 15) . Niewiarowski and Prou-Wartelle (14) and Iatridis and Ferguson (15) observed that this elaboration of fibrinolytic activity was strikingly reduced in plasma deficient in Hageman factor (Factor XII) and suggested that this clotting factor had a role in the ultimate formation of plasmin. Their hypothesis has been reinforced by the finding that the expected increase in blood fibrinolytic activity in response to physical exertion (16) or venous occlusion (17, 18) was much reduced in some Hageman factordeficient subjects.
Despite some evidence to the contrary (19) , Hageman factor does not seem to activate plasminogen directly (20, 21) ; it is likely that its role is to catalyze the formation of a plasminogen activator from its precursor (22) . In earlier studies. this activator was identified with that proactivator of plasminogen through which streptokinase brings about the formation of plasmin (23, 24) . In the present study, evidence is assembled that an activator of plasminogen can be derived from human plasma which is separable from the proactivator upon which streptokinase acts. This agent is dependent upon the presence of Hageman factor for its activation or functioning. Some characteristics of this agent, tentatively called Hageman factor-cofactor (HF-cofactor), and some properties of a partially purified preparation are described. The relationship between this substance and plasma thromboplastin antecedent (PTA, Factor XI) and plasma kallikreinogen, two other agents activated by Hageman factor, are explored. Data are furnished suggesting the existence of another plasma component which may be needed for the activation of plasminogen in the presence of Hageman factor.
METHODS
Venous blood was withdrawn from the antecubital veins of normal subjects or patients with specific coagulative disorders, using No. 18 gauge disposable needles and disposable polypropylene syringes (Monoject, Roehr Products Co., Inc., Deland, Fla.) rinsed with silicone oil (SF 96-200, General Electric Co., Waterford, N. Y.). The blood was immediately added to one-ninth volume of either sodium citrate buffer (pH 5.0, 0.13 mole/liter with respect to citrate), 0.13 M sodium citrate, or 0.1 M sodium oxalate solution. In experiments on the effect of calcium ions on the generation of fibrinolytic activity, blood was decalcified by the addition of one-tenth volume of 1.5% disodium ethylenediaminetetraacetic acid dihydrate (EDTA) in 0.7% NaCl solution.
Platelet-deficient plasma was separated from citrated plasma as described earlier (25) ; its pH was 7.4 +0.1. Oxalated or EDTA-treated plasma was separated by centrifugation at 3500 rpm for 15 min at 20C in silicone-coated cellulose nitrate tubes. Plasmas were used within 4 hr or frozen at -20'C until used.
Cohn fraction IV-1, prepared by the Blood Research Institute, Inc., was obtained from Nutritional Biochemicals Corporation, and was dissolved in barbital-saline buffer at a concentration of 10 mg/ml. Aluminum hydroxide-adsorbed plasma was prepared by mixing citrated plasma with one-tenth volume of aluminum hydroxide gel (Amphojel without Flavor, Wyeth Laboratories, Philadelphia, Pa.) for 10 min at room temperature. The plasma was separated by centrifugation at 3500 rpm for 10 min at 2'C. Calcium phosphate-adsorbed plasma was prepared in the same way by adsorbing oxalated plasma with 10 mg of calcium phosphate per milliliter. Aluminum hydroxide-adsorbed plasma and calcium phosphate-adsorbed plasma are deficient in prothrombin (Factor II), Stuart factor (Factor X), Factor VII, and Christmas factor (Factor IX).
Crude bovine thrombin (Topical Thrombin, Parke, Davis & Co., Detroit, Mich.) was treated with 2-mercaptoethanolamine hydrochloride (Nutritional Biochemical Corporation) by the method of Markus and Ambrus (26) to reduce its plasminogen content, and stored in cellulose nitrate tubes at -20°C; after thawing, it was diluted with barbital-saline buffer to the required concentration.
Bovine fibrinogen (bovine plasma Fraction I, Armour Pharmaceutical Co., Kankakee, Ill.), containing approximately 50% sodium citrate, was dissolved in barbital-saline buffer at 37°C and filtered through Whatman No. 1 paper. The concentration used was 4 mg dry weight/ml.
Human fibrinogen was provided through the kindness of Cutter Laboratories, Berkeley, Calif. It had been prepared essentially by the technique of Bergstrom and Wallen (27) in which Cohn fraction I was precipitated in the presence of e-aminocaproic acid. The preparation was dissolved in barbital-saline buffer at a concentration of 20 mg/ml.
Streptokinase (Varidase, Lederle Laboratories, Pearl River, N. Y.) was dissolved in barbital-saline buffer at a concentration of 1000 or 2000 Christensen U/ml. The preparation contained 25,000 U of streptococcal desoxyribonuclease for every 100,000 U of streptokinase.
Hirudin (Sigma Chemical Co., St. Louis, Mo.) was dissolved at a concentration of 100 ug/ml in 0.01 M sodium acetate buffer (pH 4.8). According to the manufacturer, it contained 270 U/mg.
Pyrex crushed glass (the gift of Corning Glass Works, Corning, N. Y.) which passed through a 100-mesh sieve but was retained by a 200-mesh sieve was used to prepare glassadsorbed plasma. The glass was not washed and was discarded after use.
Casein (Hammersten quality, Nutritional Biochemicals Corporation) was prepared as a 1.6% solution in 0.15 M sodium phosphate buffer (pH 7.5) by a minor modification of the method of Mullertz (28) . Alternatively, a-casein (Worthington Biochemical Corp., Freehold, N. J.) was dissolved at the same concentration without further preparation.
Lysine methyl ester (Mann Research Laboratories, New York) was dissolved at a concentration of 0.02 mole/liter in 0.1 M sodium phosphate buffer (pH 6.5) containing 0.15 M sodium chloride, and p-toluenesulfonyl-L-arginine methyl ester (Nutritional Biochemicals Corporation) was dissolved at a concentration of 0.16 mole/liter in 0.06 M sodium phosphate buffer (pH 7.4).
Hexadimethrine bromide (Polybrene, the gift of Abbott Laboratories, Chicago, Ill.), heparin (Sigma Chemical Corp.), and Liquoid (sodium polyanetholsulfonate, the gift of Roche Products Ltd., Welyn Garden City, England), were dissolved in water or in 0.01 M sodium acetate buffer (pH 5.2) at suitable concentrations. e-Aminocaproic acid (Nutritional Biochemicals Corporation) was dissolved in water at a concentration of 0.1 mole/liter; 0.1 M NaCl solution was substituted for e-aminocaproic acid as a control. C'1 esterase inhibitor was the gift of Dr. J. Partially purified Hageman factor was prepared as described earlier (20) . The relatively impure preparation used contained 2.5% protein and had been purified 175-fold.
Anti-Hageman factor globulin, adsorbed with Hageman factor-deficient or normal plasma, was prepared as reported earlier (30, 31) . 0-phenanthroline (Fisher Scientific Co., Fairlawn, N. J.) was dissolved at a concentration of 0.01 M in barbital-saline buffer.
Bradykinin, the gift of Sandoz Inc., Hanover, N. J., was dissolved at a concentration of 1 s&g/ml in 0.15 M NaCl solution and stored at -20'C in cellulose nitrate tubes. Before use, it was diluted appropriately in cellulose nitrate tubes; the solutions were highly unstable in containers made of other materials.
Crude plasma kininogen was prepared by incubating citrated plasma, which had not been allowed to come into contact with glass surfaces, at 61'C for 60 min to destroy its content of Hageman factor and plasma kallikreinogen; the plasma was centrifuged and the supernatant fluid stored at -20'C.
Glass-adsorbed plasma was prepared from citrated plasma which had been handled in silicone-coated containers. The plasma was shaken with crushed glass in silicone-coated cellulose nitrate tubes for 60 min at room temperature, using a mechanical shaker (Eberbach Corp., Ann Arbor, Mich.). The concentration of glass used was usually 200 mg/ml of plasma. After centrifugation at 3000 rpm for 10 min, the adsorbed plasma was removed with silicone-coated pipettes and stored in aliquots in silicone-coated cellulose nitrate tubes at -20'C.
"Exhausted' plasma was prepared essentially as described by Nossel (32 Lysine methyl esterase activity generated in kaolin-treated euglobulin mixtures was measured in the following way. Oxalated plasma was adsorbed with 100 mg barium sulfate (Baker Chemical Co.)/ml for 10 min at room temperature and separated by centrifugation at 3500 rpm for 5 min at 2°C to reduce its content of prothrombin. Kaolin-induced fibrinolytic activity was then generated by the method described. A mixture of 02 ml euglobulin (or buffer) and 3.0 ml lysine methyl ester was then incubated at 37°C for 121 min. 1 ml aliquots were removed at 1 and 121 min after incubation had begun, mixed with 0.5 ml 15% trichloroacetic acid, and recentrifuged. The methyl alcohol content of the samples was then estimated by the method of Siegelman, Carlson, and Robertson (35) .
Chloroform activation of euglobulin precipitates was carried out as described previously (36) Fibrinolytic activity of chloroform-activated euglobulin solutions was measured by determining the lysis time at 37°C of a clot formed from 0.2 ml euglobulin dissolved in barbitalsaline buffer, 0.4 ml bovine fibrinogen, and 0.1 ml bovine thrombin (20 NIH U/ml).
"Streptokinase-proactivator' activity was measured by incubating a mixture of 0.1 ml plasma diluted 1: 30 in barbitalsaline buffer, 0.2 ml bovine fibrinogen, 0.1 ml streptokinase (1000 Christensen U/ml) and 0.1 ml bovine thrombin (20 NIH U/ml) at 370C in 10 X 75 mm polystyrene tubes. The time between the addition of thrombin and lysis of the fibrin was noted.
Plasma plasminogen concentrations were assayed by a modification of the method of Remmert and Cohen (37) (38) (39) . Assays for antihemophilic factor (Factor VIII), Christmas factor (Factor IX), pkasma thromboplastin antecedent (PTA, Factor XI), Hageman factor (Factor XII), proaccelerin (Factor V), prothrombin (Factor II), Stuart factor (Factor X), and Factor VII were performed by techniques summarized earlier (40) .
The fibrinolytic activity of partially purified HF-cofactor after chromatography on CM columns was assessed by adding 1 ml of each fraction to 0.5 ml glass-adsorbed plasma, 0.1 ml hirudin (100 /Ag/ml), 0.25 kaolin (8 mg/ml), and 8.15 ml 0.01 M sodium acetate buffer, pH 4.8, in a 16 X 100 mm cellulose nitrate tube. After incubation at 370C for 60 min, the precipitate was deposited by centrifugation and resuspended in 0.5 ml barbital-saline buffer. The remainder of the assay was carried out as described above. Hirudin was added to prevent clotting of the glass-adsorbed plasma by coagulation factors present in the partially purified HF-cofactor preparation.
Caseinolytic activity was measured in different ways. The digestion of casein by kaolin-treated plasma, chloroformtreated plasma, and partially purified Hageman factorcofactor was measured by a modification of the method of Remmert and Cohen (37) . One part of the mixture to be tested was mixed with three parts of 1.6% casein and incubated at 37°C for 4 hr. At 2 min and again at 4 hr aliquots of the mixture were removed and mixed with an equal volume of 10% trichloroacetic acid. The tubes were centrifuged after a minimum of 15 min, the supernatant solutions filtered through glass wool, and their optical densities read at 280 mg in a Beckman Model DU spectrophotometer equipped with a Gilford Instrument Company absorbance meter. Optical density was converted to micrograms of tyrosine per milliliter by reference to a standard tyrosine solution. To test the caseinolytic activity of kaolintreated plasma, two parts of plasma, one part of kaolin (8 mg/ml), and 37 parts of 0.01 -M sodium acetate buffer (pH 4.8) were incubated in cellulose nitrate tubes at 37°C.
At intervals, aliquot tubes were centrifuged and the deposited euglobulin:kaolin precipitate suspended in 1 ml of 0.15 M sodium phosphate (pH 7.5). Incubation at 37°C was then restarted after the addition of 3 ml of 1.6% casein. Casein hydrolysis of chloroform-activated euglobulin solutions was measured by incubating 0.8 ml euglobulin, in 0.15 M sodium phosphate buffer (pH 7.5), and 3 ml 1.6% casein in the same manner. The caseinolytic activity of partially purified HFcofactor was determined by incubating suitable amounts, in 0.01 M sodium acetate buffer (pH 5.2), glass-treated plasma (adjusted to pH 5.2 with 1.0 N hydrochloric acid just before use), kaolin suspension, and acetate buffer at 37°C for periods up to 90 min in cellulose nitrate tubes. The mixtures were then centrifuged at 2'C for 5 min at 3500 rpm, the precipitates suspended in 0.15 M sodium phosphate buffer and three volumes of casein then added. The effect of inhibitors was tested by substituting 1 ml of the agent to be tested for 1 ml of acetate buffer before the first period of incubation. The inhibitor was added to control tubes after this period and before centrifugation. The kallikrein-like activity of partially purified HFcofactor was estimated by incubation 0.1 ml of 0.01 M o-phenanthroline, 0.1 ml crude kininogen, 0.1-0.6 ml of the fraction to be tested, and sufficient barbital-saline buffer to bring the volume of the mixture to 1.0 ml, in polystyrene tubes for 15 min at 370C. The effect of aliquots of this mixture was then tested upon the rat uterus by a technique used earlier (41) .
Acrylamide-gel disc electrophoresis was performed as described previously (42) .
The esterolytic activity of HF-cofactor was measured by incubating 2 ml of 0. 
RESULTS
I. The generation of fibrinolytic activity in normal plasma incubated with kaolin. As Niewiarowski (14) and latridis (15) and their associates reported, fibrinolytic activity generated when diluted, acidified normal plasma was incubated with kaolin. At the same time, the mixture acquired the capacity to hydrolyze casein and lysine methyl ester, two substrates of plasmin. These properties were present in euglobulin precipitates separated after incubation (Fig. 1) .
The rate of generation of fibrinolytic activity increased with the concentration of kaolin over the range 0.5-2 mg/ml of plasma; no further increase occurred with higher concentrations. Kaolin appeared to influence the generation of fibrinolytic activity; if plasma was diluted with acetate buffer and incubated for 1 hr, no appreciable fibrinolytic activity was detected in the euglobulin precipitate even though kaolin was added before assay.
The generation of fibrinolytic and caseinolytic properties required factors in both the euglobulin precipitate and the supernatant fraction of acidified, diluted plasma. No (Fig. 2) .
II. Evidence for the participation of Hageman factor in the kaolin-induced generation of fibrinolytic activity. As Iatridis and Ferguson (44) reported, the kaolininduced generation of fibrinolytic activity was defective in plasma, deficient in Hageman factor, but was normal in plasmas deficient in other clotting factors. Thus, normal activity evolved in plasmas deficient in PTA, Christmas factor, antihemophilic factor, Stuart factor, factor VII, or proaccelerin, as well as in plasmas adsorbed with aluminum hydroxide gel or calcium phosphate to reduce their content of prothrombin, Factor VII, Christmas factor, and Stuart factor. Particular attention was paid to plasma from PTA-deficient patients because these contained 5-10% of normal PTA activity. Two such plasmas were diluted with glass-adsorbed plasma (see section IV) and the fibrinolytic activity generated compared with similarly diluted normal plasma. The PTA-deficient plasmas behaved like normal plasma when each was diluted 20-fold with glass-adsorbed plasma.
The importance of Hageman factor in the evolution of fibrinolytic activity was confirmed by demonstrating that the addition of partially purified Hagemen factor corrected the defect in plasma deficient in this agent (Table  I) . Similarly, specific anti-Hageman factor rabbit globulin greatly diminished the kaolin-induced generation of fibrinolytic activity in normal plasma. For example, the clot lysis time of normal plasma, treated with kaolin, was 16 min, whereas that of the same plasma, treated with specific antiserum, was 136 min. The specificity of the antiserum was assured by its absorption with Hageman factor-deficient plasma.
The small quantities of normal plasma needed to correct defective generation of fibrinolytic activity in Hageman factor-deficient plasma (Fig. 3) are consistent with the possibility that Hageman factor acts enzymatically in the kaolin-induced generation of fibrinolytic activity. Hageman factor-deficient plasma + water 127 Glass-adsorbed plasma + Hageman factor 101 Glass-adsorbed plasma + water 98 Normal plasma + Hageman factor 7 Normal plasma + water 7.5 * 0.1 ml purified Hageman factor (5 mg/ml) or 0.1 ml water added to 0.5 ml of each plasma immediately before the addition of kaolin, dilution with acetate buffer, and incubation at 370C for 60 min (see Methods).
III. Factors influencing the kaolin-induced generation of fibrinolytic activity. Serum, obtained from whole blood diluted with one-ninth volume of 0.15 M NaCl and kept at 370C for 4 hr, generated approximately the same degree of fibrinolytic activity as citrated plasma prepared from the same sample of blood.
The ability of plasma to generate fibrinolytic activity in the presence of kaolin was not diminished by incubation at 370C for 48 hr, but was abolished by incubation at 560C for 30 min; such treatment had no appreciable effect upon the plasma's content of Hageman factor and plasminogen. Plasmas adjusted to pH 2.0 or pH 10.0 by addition of 0.1 N hydrochloric acid and 0.1 N sodium hydroxide, respectively, and then neutralized after 10 min, had a striking loss of fibrinolytic activity, while retaining their original content of Hageman factor and plasminogen. These experiments suggested that besides Hageman factor and plasminogen one or more other agents were needed to generate fibrinolytic activity.
The kaolin-induced generation of fibrinolytic activity was temperature-dependent and was maximal at 370C. The development of fibrinolytic activity was also pHdependent. The influence of hydrogen ion concentration was tested by measuring the generation of fibrinolytic activity in the presence of sodium acetate buffers of pH 4.8-6.0 (0.01 mole/liter with respect to acetate). To exaggerate any differences, the experiment was performed on a mixture of 5% normal and 95% glassadsorbed plasma. Generation was maximal at pH 5.2. Visible euglobulin precipitation decreased above this pH, and, concurrent with its virtual absence at pH 6.0, generation of fibrinolytic activity was markedly reduced. The generation of fibrinolytic activity was also influenced by the molarity of the sodium acetate buffer. As the molarity was increased from 0.01 to 0.20, generation was progressively and markedly reduced. This reduction was due largely to acetate ion rather than to the increase in ionic strength per se, for there was only a minimal decrease in the evolution of fibrinolytic activity when plasma was incubated with 0.01 M sodium acetate in increasing concentrations of NaCl.
Calcium did not seem necessary for the kaolin-induced generation of fibrinolytic activity. The activity evolved during 60 min incubation of EDTA-treated plasma at 370C was the same whether calcium ions were absent or were added to a concentration of 5 mmoles/liter. The lysis time doubled when the concentration of calcium was increased to 10 mmoles/liter. Thus, calcium ions at concentrations sufficient to overcome the chelating effect of EDTA were, in fact, inhibitory. The activity of other ions was not investigated.
IV. The effect of adsorption of plasma with crushed glass or diatomaceous earth on its capacity to generate fibrinolytic activity. The experiments described thus far suggested that factors additional to Hageman factor and plasminogen were needed for the generation of fibrinolytic activity under the circumstances described. In agreement with this, treatment of normal plasma with crushed glass at a concentration of 200 mg/ml lengthened its kaolin-induced lysis time, but did not reduce its content of Hageman factor or plasminogen (Table II) . In these experiments, the assay for Hageman factor was not affected by the presence of activated PTA, resulting from treatment of plasma with glass. If such glasstreated plasma was incubated at 370C overnight, its content of PTA was reduced to less than 1%. but the concentration of Hageman factor appeared to be unaltered.
Higher concentration of glass lengthened the lysis time further, but at the same time removed increasing quantities of Hageman factor. The generation of fibrinolytic activity in glass-treated plasma was not increased by the addition of partially purified Hageman factor (Table I) . Conversely, as little as 20% Hageman factordeficient plasma significantly increased the fibrinolytic potential of glass-treated plasma. Presumably, treatment of normal plasma with glass had removed one or more components present in Hageman factor-deficient plasma and needed for the kaolin-induced generation of fibrinolysis.
Citrated plasma, adsorbed with diatomaceous earth (Celite 512) at a concentration of 50 mg/ml and then incubated at 370C for 6 hr, behaved as if depleted of additional factors required for fibrinolysis besides those Whatever the nature of the agents removed from plasma by glass or diatomaceous earth, they were not needed for activation of plasminogen by streptokinase. Adsorption of normal plasma with crushed glass at concentrations which greatly lengthened its kaolin-induced lysis time, did not alter its streptokinase-proactivator activity (Table III) . Several different adsorbents were tested for their ability to remove factors needed to speed fibrinolysis. No correlation was found between the residual streptokinase-proactivator activity and the plasma component needed for the generation of fibrinolytic activity in the presence of kaolin (Table IV) . These experiments provided further evidence for their separate identity. In the experiment depicted in Table IV rations of glass-adsorbed plasma or plasma deficient in Hageman factor had greatly reduced fibrinolytic and caseinolytic activities. Hexadimethrine bromide inhibits Hageman factor (48) and the generation of fibrinolytic activity in the presence of kaolin (49) . The addition of hexadimethrine bromide to the euglobulin fraction of normal plasma at a final concentration of 20 ,sg/ml, before treatment with chloroform, markedly reduced the development of proteolytic activity (Table VII) .
These experiments suggest roles for Hageman factor and for an agent or agents missing in glass-treated plasma in the evolution of plasmin in the presence of chloroform.
VII. Comparison of crude Celite eluates from normal and Hageman factor-deficient plasma. Fibrinolytic activity developed when a crude eluate of normal plasma was incubated with glass-adsorbed or Hageman factordeficient plasma (Table VIII) . The same result was obtained whether or not kaolin was present, as if the effect of surface-active agents was upon the generation of the activity found in Celite eluates. In contrast, Celite eluates of Hageman factor-deficient plasma induced fibrinolytic activity only if kaolin was added. Thus, the component in Celite eluates which was needed for the generation of fibrinolytic activity was effective only in the presence of Hageman factor. In experiments in which eluates were prepared from Hageman factordeficient plasma, Hageman factor was furnished by the glass-adsorbed plasma to which it was added, and in this case required the addition of kaolin to function.
VIII. The partial purification and properties of Hageman factor-cofactor. In the preceding section, evidence was provided that a factor could be removed from normal or Hageman factor-deficient plasma by adsorption onto diatomaceous earth, and that this substance could 4 The chromatography of HF-cofactor on a CM-cellulose column. The adsorbed protein was eluted by a buffer gradient between 0.067 M sodium phosphate, pH 6, and 0.067 M sodium phosphate, pH 6, containing 0.5 M NaCl. Lysis times were converted into units of fibrinolytic activity by utilizing a double logarithmic plot of times against units, 10 U being assigned arbitrarily to a lysis time of 5 min. Fibrinolytic activity * 0, protein 0 O.
then be eluted in active form. Further purification of the agent enhancing fibrinolysis was achieved by chromatography of Celite eluates upon columns of CM-cellulose (Fig. 4) . All preparations were in an activated form and corrected the defective generation of fibrinolytic activity in glass-adsorbed or Hageman factor-deficient plasma. Such preparations, tentatively named Hageman Incubation time (min) FIGURE 5 The influence of Hageman factor-cofactor upon the generation of caseinolytic activity. A mixture of 0.5 ml glass-treated plasma (adjusted to pH 5.2 just before use by addition of 1 N hydrochloric acid), 0-9 ml HF-cofactor (88 ,ug protein/ml) in 0.01 M sodium acetate buffer (pH 5.2), 0.5 ml kaolin (8 mg/ml), and sufficient 0.01 M sodium acetate buffer to bring the volume to 10 ml was incubated at 370C for 90 min. At intervals, aliquot tubes were centrifuged at 20C and the precipitate suspended in 1.25 ml 0.15 M sodium phosphate buffer (pH 7.4). Casein hydrolysis during the succeeding 4 hr was measured upon addition of 3.75 ml 1.6% casein to each tube.
factor-cofactor (HF-cofactor), induced caseinolytic activity in glass-adsorbed plasma (Fig. 5) . Although zero order kinetics were not achieved, reducing the concentration of HF-cofactor fourfold resulted in only about a 40% reduction in the caseinolytic activity generated in 90 min. In contrast, the caseinolytic activity generated in the presence of a fixed amount of HF-cofactor was a linear function of the concentration of glassadsorbed plasma (Fig. 6 ). These FIGURE 6 The influence of glass-treated plasma upon the generation of caseinolytic activity. A mixture of 0-0.5 ml glass-treated plasma (adjusted to pH 5.2 just before use by addition of 1 N hydrochloric acid), 9 ml HF-cofactor (114 A&g protein/ml) in 0.01 M sodium acetate buffer (pH 5.2), 0.5 ml kaolin (8,g/ml), and sufficient 0.01 M sodium acetate buffer to bring the volume to 10 ml was incubated at 370C
for 90 min. The caseinolytic activity of successive aliquot tubes was determined as in the experiment depicted in Fig. 5 .
patible with the view that HF-cofactor induced fibrinolytic activity from a precursor in glass-adsorbed plasma, presumably the plasminogen which it contained. The preparations of HF-cofactor were not pure. In different experiments, two or three faint lines could be identified by disc electrophoresis in the region comparable to that of gamma globulin in plasma. Constant contaminants of HF-cofactor, prepared by CM-cellulose chromatography, were activated PTA-and kallikrein-like activity, the latter demonstrated by its capacity to initiate the formation of kinins from a kininogen preparation. As best as could be judged, these agents were present in roughly the same concentration as HFcofactor, a relationship maintained after further chromatography upon columns of DEAE-cellulose. The preparations were free of all other clotting factors with the possible exception of activated Hageman factor, the assay for which was vitiated by the presence of activated PTA. Most preparations contained traces of plasmin, demonstrable by prolonged incubation with casein but insufficient in themselves to lyse fibrin clots of bovine fibrinogen and thrombin. Plasminogen could not be detected by addition of streptokinase. Some preparations contained traces of thrombin, neutralized by the addition of hirudin and removable by DEAE-cellulose chromatography.
As might be expected from these considerations, preparations of HF-cofactor hydrolyzed p-toluenesulfonyl-Larginine methyl ester, a substrate of activated PTA and plasma kallikrein. Thus, it was not possible to attribute esterolytic activity to HF-cofactor. Indirect evidence of the hydrolytic nature of HF-cofactor was obtained by exposing preparations to PMSF at a concentration of 0.005 mole/liter. Such treatment sharply decreased the generation of fibrinolytic and caseinolytic activity in a mixture of HF-cofactor and exhausted plasma. In one experiment, for example, a mixture containing untreated HF-cofactor induced fibrinolysis in 3.5 min, one containing HF-cofactor exposed to 10% isopropanol induced fibrinolysis in 5 min, while one containing HF-cofactor exposed to 0.005 M PMSF in isopropanol did not lyse a clot during a period of 5 hr. Similarly, HF-cofactor treated with PMSF generated less than one-fifth the caseinolytic activity of untreated HF-cofactor. Since PMSF is an inhibitor of many hydrolytic enzymes, these observations imply that HF-cofactor may be an enzyme of this type.
HF-cofactor was separable from activated PTA and plasma kallikrein by several means. The apparent molecular weights of activated PTA and HF-cofactor were identical, as determined by filtration of HF-cofactor through columns of Sephadex G200, approximately 165,000 in each of four experiments. But PTA-deficient plasma was as good a source of HF-cofactor as normal plasma, and a preparation of-Cohn fraction IV-1 contained appreciable HF-cofactor and kallikrein-like activity, but was devoid of detectable PTA.
The distinction between HF-cofactor and plasma kallikrein rests upon several grounds. The molecular weight of plasma kallikrein, as determined by Sephadex G200 filtration, was 130,000. A second component with a molecular weight of 95,000 was detected in one of four experiments. These values are distinct from those obtained in studying activated PTA and HF-cofactor, but, within the limits of error of our technique, the same as those attributed to plasma kallikrein I and III by Colman, Mattler, and Sherry (50) . Acidification of partially purified HF-cofactor at pH 2.0 did not reduce its content of plasma kallikrein, while decreasing the generation of caseinolytic activity and the concentration of activated PTA significantly. E-Aminocaproic acid, at a concentration in the mixture of 0.01 mole/liter, inhibited the generation of caseinolytic activity in a mixture of HF-cofactor and glass-treated plasma, but was without effect the kallikrein-like activity of the preparation. Heparin, at a concentration of 1.25 U/ml, and Liquoid, at a concentration of 6.25 ALg/ml, sharply reduced the caseinolytic activity generated in a mixture of partially purified HF-cofactor and glass-treated plasma but was without effect upon the generation of kinins; the significance of this observation is clouded by the fact that obvious precipitation occurred in the mixture of HF-cofactor and glass-treated plasma upon the addition of heparin or Liquoid, so that their effect may have been upon some other component of the test system. In an earlier study, C'1 esterase inhibitor, at concentrations inhibiting kallikrein, did not alter the rate at which fibrinolytic activity in kaolin-treated euglobulin preparations (51). The same result obtained when C'1 esterase inhibitor, at a concentration of 12 U/ml, was incubated for 10 min with HF-cofactor before incubation with glass-treated plasma and the caseinolytic activity generated thereafter was tested. Inhibition of plasmin-like activity by C'1 esterase inhibitor, noted earlier (51) , was again demonstrable.
There was no significant loss of HF-cofactor activity during incubation at 37°C for 4 hr, but a substantial decline in activity had occurred in 48 hr. Its stability at higher temperatures is shown in Fig. 7 . IX. Evidence for the existence of an additional plasma factor which participates in the generation of fibrinolytic activity. To localize the components needed to generate fibrinolytic activity, glass-adsorbed plasma was mixed with buffer or with HF-cofactor. Each mixture was then diluted and acidified, and the euglobulin fraction separated from the supernatant solution by centrifugation. Experiments in which the euglobulin and supernatant fractions of the two plasmas were interchanged demonstrated that the activated form of partially purified HF-cofactor was in the euglobulin precipitate (Table  IX) . In contrast, a component present in the supernatant fraction was necessary for kaolin-induced generation of fibrinolytic activity. Since euglobulin fractions of plasma contain both Hageman factor and plasminogen, the possibility was raised by these experiments that still another agent was needed for the generation of fibrinolytic activity. In agreement with this, virtually no caseinolytic activity evolved when preparations of HF-cofactor were incubated with plasminogen; in contrast, HF-cofactor readily induced caseinolytic activity in glass-adsorbed plasma.
Several explanations were explored for the poor yield of plasmin when HF-cofactor was incubated with plasminogen. This did not appear to be related to the Hageman factor content of glass-adsorbed plasma, for the addition of purified Hageman factor did not influence the yield of plasmin in a mixture of plasminogen and HF-cofactor. Two possible further explanations are reduced sensitivity of the purified plasminogen preparation or that a further plasma factor was required for the generation of plasminogen activator, as the experiments described in the last paragraph suggested. Evidence for the latter suggestion is provided by a study of the effect of the noneuglobulin, supernatant fraction of exhausted plasma upon fibrinolysis. Exhausted plasma, lacking Hageman factor and HF-cofactor, was acidified and diluted and the euglobulin fraction separated by centrifugation (Table X) FIGuRE 7 The heat stability of partially purified HFcofactor. The HF-cofactor preparation (68 jAg protein/ml) was kept at the indicated temperature for 30 min. 0.75 ml HF-cofactor or 0.01 M sodium phosphate buffer (pH 7.5), 0.5 ml glass-adsorbed plasma, 0.25 ml kaolin (8 mg/ml), 0.1 ml hirudin (100 jag/ml), and 8.5 ml 0.01 M sodium acetate buffer (pH 4.8) were incubated for 60 min at 370C before assay of the general fibrinolytic activity. In the absence of HF-cofactor the lysis time was 128 min. (2) 159 4. Euglobulin precipitate of (1) +supernatantof (2) 11 * 1 ml HF-cofactor (68 ,ug protein/ml) or 0.01 M sodium phosphate buffer (pH 7.5), 0.5 ml glass-adsorbed plasma, 0.25 ml 0.01 M sodium acetate buffer (pH 4.8), 0.1 ml hirudin (100 MAg/ml), and 8.5 ml 0.01 M sodium acetate buffer (pH 4.8) (20) , an observation agreed to by Schoenmakers, Kurstjens, Haanen, and Zilliken (21) . These observations have been confirmed; fibrinolytic activity did not develop upon the addition of kaolin to plasma rich in Hageman factor and plasminogen, but depleted of certain other agents by adsorption with glass. These experiments imply that treatment of plasma with crushed glass and other insoluble materials removes one or more components needed for the generation of fibrinolytic activity in the presence of a surface. This property of crushed glass is contrary to a previous report (52) ; it is likely that this discrepancy results from the use of glass of different particle size for adsorption.
Solutions of ellagic acid activate Hageman factor in the absence of surface contact (45) ; its addition to normal plasma might be expected to initiate the reaction leading to plasmin formation, and supporting experimental data have been reported (53) . We found that ellagic acid induced some generation of fibrinolytic activity in acidified, diluted plasma, but only when present in such high concentrations that much insoluble material was present. It is likely, therefore, that its effect was mediated through its surface properties rather than by its specific activation of Hageman factor alone. The implication is that activation of Hageman factor and the presence of a suitable surface are required for the generation of fibrinolytic activity.
The mechanism by which proteolytic activity develops in the euglobulin fraction of plasma during incubation with chloroform has been the subject of debate for a number of decades. We have found that the development of proteolytic activity in chloroform-treated euglobulins prepared from glass-adsorbed plasma or Hageman factor-deficient plasma was greatly diminished in comparison to similarly treated euglobulins prepared from normal plasma or from plasmas deficient in other factors which participate in the intrinsic coagulation mechanism. In addition, hexadimethrine bromide, an inhibitor of Hageman factor (49) , reduced the ability of plasma euglobulins to develop proteolytic activity after chloroform treatment. These findings suggest that the formation of proteolytic activity in euglobulins shaken in glass with chloroform is mediated through the activation of Hageman factor rather than through autocatalysis. Such an explanation is in keeping with the finding that preparations of partially purified plasminogen cannot be activated by chloroform (54) . The role of chloroform itself remains uncertain, but it seems likely that it destroys the inhibitory activity remaining in the euglobulin fraction (55) .
The experiments described have suggested the hypothesis that one or more additional agents in plasma are required for the activation of plasminogen by activated Hageman factor. No fibrinolytic or caseinolytic activity appeared in plasma which had previously been treated with glass in a specific way. This defect in glass-treated plasma could be corrected by small amounts of Hageman factor-deficient plasma, or by a fraction of such plasma prepared by adsorption of the active principle upon Celite and its subsequent elution. But Hageman factordeficient eluates were effective only if kaolin was added to the mixture; presumably, the kaolin served to activate Hageman factor in the glass-treated plasma. In contrast, incubation of Hageman factor-deficient plasma with a Celite eluate prepared from normal plasma induced the generation of fibrinolytic activity. Under these conditions we presume that the effective principle in the Celite eluate was activated during its preparation by Hageman factor in the normal plasma, itself activated by the Celite. These experiments resemble those reported by Iatridis and Ferguson (22) , Onchi (24) , and Mackay, Maycock, and Combridge (56) although their interpretations differed from ours.
The existence of an agent in normal plasma, activated by contact with Celite, was further demonstrated by the separation of an activator of plasminogen by chromatography of Celite eluates upon columns of CM-cellulose. This agent, when added to diluted, acidified Hageman factor-deficient plasma, induced the generation of plasmin even in the absence of a surface. Tentatively, the substance present in Hageman factor-deficient plasma and absent from glass-adsorbed plasma and needed for the formation of plasminogen by Hageman factor has been designated as Hageman factor-cofactor; this nonspecific name underscores our uncertainty of its physiologic role. While the agent separated by chromatography is presumably the same as that present in crude Celite eluates, the possibility cannot be excluded that it is yet another plasminogen activator. HF-cofactor, prepared by CM-cellulose chromatography, sometimes contained traces of thrombin; these traces could be removed by further chromatography upon DEAE-cellulose.
CM-cellulose eluates containing HF-cofactor were rich in activated PTA and in a plasma kallikrein, both of which are agents activated from their respective precursors by activated Hageman factor. Experiments are described which appeared to separate HF-cofactor from the other two agents. Hageman factor-cofactor could be prepared from plasma congenitally deficient in PTA and from a preparation of Cohn fraction IV-1 devoid of PTA-like activity. Its apparent molecular weight was about 165,000, in contrast to that of plasma kallikrein in preparations of HF-cofactor, which was 130,000, with a second component in one of four experiments with a mol wt of 95,000.
Further, acidification to pH 2.0 or the addition of e-aminocaproic acid, heparin, or Liquoid inhibited the formation of caseinolytic activity in mixtures of HFcofactor and glass-adsorbed plasma without affecting the kallikrein-like activity of HF-cofactor preparations under the conditions used. Conversely, C'1 esterase inhibitor was without effect upon the generation of fibrinolytic or caseinolytic activity at concentrations inhibiting plasma kallikrein (51) . These observations suggest that HF-cofactor, PTA, and plasma kallikrein are functionally separate entities. They do not prove that these substances do not exist in nature as a single entity, altered by our separation procedures. This assumption requires, however, that each property is altered in a different manner by pH and the various inhibitors tested.
To further complicate this system, evidence was obtained that another substance required for the activation of plasminogen by Hageman factor may be present in plasma. Plasma was "exhausted" of Hageman factor and HF-cofactor, and its euglobulin fraction separated by acidification and dilution. The supernatant fraction, after centrifugation, increased the potential of HF-cofactor to generate fibrinolytic activity. Our observations would be compatible with the hypothesis that we have isolated in the CM-cellulose fraction a plasma component which has been activated under the influence of Hageman factor during its preparation. This plasma component requires a further factor, present in the euglobulin supernatant, for the formation of a plasminogen activator.
The presence of small amounts of an activator of plasminogen can be detected in blood withdrawn from the circulation and the level is greatly enhanced in a variety of circumstances (12) . The origin of this plasminogen activator is unproven although there is evidence that the vascular endothelium may be a source under certain circumstances. From the data of previous investigators (22) and the results of the present study we conclude that the circulating blood contains components which, on activation of Hageman factor, interact to form an activator of plasminogen. Further investigation is required, however, to unravel the complexities of this system and to elucidate the relationship of this plasminogen activator to that which is present in normal human plasma.
The studies presented serve once again to remind us that the body's defense mechanism is complicated. However appealing the view that the plasma contains separate pathways leading to clotting fibrinolysis, inflammation, or the activation of complement, our experiments emphasize instead the interwoven reactions among these systems.
